Claritas Genomics Secures $15M in Series B Funding

claritas-logoClaritas Genomics, a Cambridge, MA-based clinical genetic diagnostic testing company, secured $15m in Series B funding.

The round was led by WuXi NextCODE Genomics with participation from existing investors Boston Children’s Hospital, Cerner Corporation and Cincinnati Children’s Hospital Medical Center.

The company intends to use the funds to expand its commercial operations, launch new sequencing-based tests for diagnosis of pediatric genetic disorders and continue to build its network of clinical pediatric disease experts.

Led by Patrice Milos, Ph.D., CEO, Claritas clinical expertise of pediatric specialists with next generation sequencing technology to provide clinicians with a full range of services to navigate the landscape of genetic diagnostics.



Join the discussion